Li Dean Y — SEC insider filings
SEC reporting owner CIK 1837016. 53 insider filings on record with FilingPulse; latest filed 2026-10-02.
Transaction summary — filings shown
Covers the 50 most recent of 53 filings on record, filed 2021-05-04 to 2026-10-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 11 legs across 7 filings — 123,124 shares, $6,331,520 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 70.
- Largest priced transaction: sale of 14,702 shares @ $125.50 ($1,845,083) in Merck & Co., Inc., filed 2024-02-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Merck & Co., Inc. (MRK) | Executive VP & President, MRL | 19 | — | 3 legs · 40,024 sh · $4,839,751 | 38 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | Director | 31 | — | 8 legs · 83,100 sh · $1,491,768 | 32 |
Insider filings — Li Dean Y
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-02 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 3,378 @ $0 | EDGAR |
| 2026-07-02 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 3,747 @ $0 | EDGAR |
| 2026-06-22 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 88,424 @ $0 | EDGAR |
| 2026-05-07 | 4 | Merck & Co., Inc. (MRK) | Grant/award (A): 19,885 (derivative) @ $0 · Grant/award (A): 58,207 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Merck & Co., Inc. (MRK) | Option exercise (M): 4,722 @ $110.03 · Tax withholding (F): 2,326 @ $110.03 · Option exercise (M): 4,722 (derivative) @ $0 | EDGAR |
| 2026-04-02 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 3,268 @ $0 | EDGAR |
| 2026-02-10 | 4 | Merck & Co., Inc. (MRK) | Sale (S): 10,235 @ $117.52 | EDGAR |
| 2026-02-06 | 4 | Merck & Co., Inc. (MRK) | Option exercise (M): 15,087 @ $56.04 · Sale (S): 15,087 @ $118.77 · Option exercise (M): 15,087 (derivative) @ $0 | EDGAR |
| 2026-01-28 | 4 | Merck & Co., Inc. (MRK) | Grant/award (A): 20,469 @ $107.40 | EDGAR |
| 2026-01-06 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 2,381 @ $0 | EDGAR |
| 2025-10-03 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 1,961 @ $0 | EDGAR |
| 2025-07-03 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 1,949 @ $0 | EDGAR |
| 2025-06-23 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 22,016 @ $0 · Grant/award (A): 44,031 (derivative) @ $0 | EDGAR |
| 2025-05-01 | 4 | Merck & Co., Inc. (MRK) | Grant/award (A): 14,166 (derivative) @ $0 · Grant/award (A): 64,481 (derivative) @ $0 | EDGAR |
| 2025-04-03 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 2,268 @ $0 | EDGAR |
| 2025-01-29 | 4 | Merck & Co., Inc. (MRK) | Grant/award (A): 32,621 @ $97.94 | EDGAR |
| 2025-01-06 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 1,647 @ $0 | EDGAR |
| 2024-10-04 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 1,925 @ $0 | EDGAR |
| 2024-07-03 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 1,592 @ $0 | EDGAR |
| 2024-06-05 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 13,097 @ $0 · Grant/award (A): 26,193 (derivative) @ $0 | EDGAR |
| 2024-05-02 | 4 | Merck & Co., Inc. (MRK) | Grant/award (A): 65,625 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 1,267 @ $0 | EDGAR |
| 2024-02-12 | 4 | Merck & Co., Inc. (MRK) | Option exercise (M): 14,702 @ $62.07 · Sale (S): 14,702 @ $125.50 · Option exercise (M): 14,702 (derivative) @ $0 | EDGAR |
| 2024-01-24 | 4 | Merck & Co., Inc. (MRK) | Grant/award (A): 25,760 @ $119.43 | EDGAR |
| 2024-01-11 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Sale (S): 28,038 @ $13.65 · Sale (S): 962 @ $14.03 | EDGAR |
| 2024-01-04 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 1,203 @ $0 | EDGAR |
| 2023-10-04 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 1,659 @ $0 · Gift (G): 627,705 @ $0 | EDGAR |
| 2023-07-06 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 1,609 @ $0 | EDGAR |
| 2023-06-21 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 12,612 @ $0 · Grant/award (A): 25,224 (derivative) @ $0 | EDGAR |
| 2023-05-04 | 4 | Merck & Co., Inc. (MRK) | Grant/award (A): 77,455 (derivative) @ $0 | EDGAR |
| 2023-05-03 | 4 | Merck & Co., Inc. (MRK) | Option exercise (M): 1,062 @ $115.47 · Tax withholding (F): 524 @ $115.47 · Option exercise (M): 1,062 (derivative) @ $0 | EDGAR |
| 2023-04-05 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 1,724 @ $0 | EDGAR |
| 2023-01-25 | 4 | Merck & Co., Inc. (MRK) | Grant/award (A): 3,275 @ $109.88 | EDGAR |
| 2023-01-05 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 1,573 @ $0 | EDGAR |
| 2022-10-05 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 1,092 @ $0 | EDGAR |
| 2022-07-06 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 1,409 @ $0 | EDGAR |
| 2022-06-16 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 18,145 @ $0 · Grant/award (A): 36,290 (derivative) @ $0 | EDGAR |
| 2022-05-05 | 4 | Merck & Co., Inc. (MRK) | Grant/award (A): 75,728 (derivative) @ $0 | EDGAR |
| 2022-05-04 | 4 | Merck & Co., Inc. (MRK) | Option exercise (M): 773 @ $87.65 · Tax withholding (F): 381 @ $87.65 · Option exercise (M): 773 (derivative) @ $0 | EDGAR |
| 2022-05-03 | 4 | Merck & Co., Inc. (MRK) | Option exercise (M): 1,061 @ $88.69 · Tax withholding (F): 523 @ $88.69 · Option exercise (M): 1,061 (derivative) @ $0 | EDGAR |
| 2022-04-05 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 1,544 @ $0 | EDGAR |
| 2022-02-28 | 4 | Merck & Co., Inc. (MRK) | Grant/award (A): 3,023 @ $73.51 | EDGAR |
| 2022-01-05 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 659 @ $0 | EDGAR |
| 2021-12-09 | 4/A | RECURSION PHARMACEUTICALS, INC. (RXRX) | Sale (S): 5,626 @ $20.04 · Sale (S): 13,474 @ $20.20 | EDGAR |
| 2021-12-09 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Sale (S): 14,900 @ $20.44 · Sale (S): 1,000 @ $21.06 | EDGAR |
| 2021-11-19 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Sale (S): 5,626 @ $20.04 · Sale (S): 13,474 @ $20.20 | EDGAR |
| 2021-10-05 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 543 @ $0 | EDGAR |
| 2021-07-06 | 4 | RECURSION PHARMACEUTICALS, INC. (RXRX) | Grant/award (A): 330 @ $0 | EDGAR |
| 2021-05-06 | 4 | Merck & Co., Inc. (MRK) | Option exercise (M): 694 @ $75.98 · Tax withholding (F): 238 @ $75.98 · Grant/award (A): 91,837 (derivative) @ $0 · Option exercise (M): 694 (derivative) @ $0 | EDGAR |
| 2021-05-04 | 4 | Merck & Co., Inc. (MRK) | Option exercise (M): 1,030 @ $74.50 · Tax withholding (F): 354 @ $74.50 · Option exercise (M): 750 @ $74.50 · Tax withholding (F): 257 @ $74.50 · Option exercise (M): 1,030 (derivative) @ $0 · Option exercise (M): 750 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-02-25 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1837016 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs